课题基金 / 基金详情

ORAL GI26257OX IN PATIENTS W TYPE II DIABETES MELLITUS

ORAL GI26257OX IN PATIENTS W TYPE II DIABETES MELLITUS
II 型糖尿病患者口服 GI26257OX
批准号:
6263497
负责人:
JANET MCGILL
金额:
$2.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

JANET MCGILL的其他基金

相似基金

相关文献

中文摘要
翻译
GI262570X是一种有效的、选择性的非噻唑烷二酮PPAR激动剂。在2型糖尿病(DM)的啮齿动物模型中,该化合物具有降血糖和降血脂的作用。因此,GI262570X具有改善2型糖尿病相关的高血糖和血脂异常的潜力。在体外,它的效力约为曲格列酮(一种噻唑烷二酮类抗糖尿病药物)的1000倍,并对PPAR受体显示出更高的选择性。据推测,这种更大的效力和选择性将转化为改善的血糖控制(通过糖化血红蛋白来衡量)。本研究将探讨GI262570X治疗2型糖尿病的安全性和有效性。
英文摘要
GI262570X is a potent, selective, non-thiazolidinedione PPAR agonist. This compout has demonstrated anithyperglycemic and lipid-lowering activity in rodent models of Type 2 diabetes mellitus (DM). GI262570X, therefore, has the potential to ameliorate the hyperglycemia and dyslipidemia associated with Type 2. It is about 1000-fold more potent than troglitazone (a thiazolidinedione antidiabetic agent) in vitro and shows greater selectivity for the PPAR receptor. It is hypothesized that this greater potency and selectivity will translate into improved glycemic control (as measured by glycosylated hemoglobin, HbA). This study will investigate the safety and efficacy of GI262570X in patients with Type 2 DM..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTRA AND INTERSUBJECT VARIABILITY IN ABSORPTION OF SUBCUTANEOUS INSULIN
  • 批准号:
    6113031
  • 项目类别:
  • 资助金额:
    $2.44万
  • 财政年份:
    1998
  • 负责人:
    JANET MCGILL
  • 依托单位:
16 WEEK MULTICENTER CLINICAL TRIAL COMPARING H0E901 W/ NPH HUMAN INSULIN
  • 批准号:
    6113033
  • 项目类别:
  • 资助金额:
    $2.44万
  • 财政年份:
    1998
  • 负责人:
    JANET MCGILL
  • 依托单位:
EARLY DIABETES INTERVENTION PROGRAM (EDIP)
  • 批准号:
    6263500
  • 项目类别:
  • 资助金额:
    $2.44万
  • 财政年份:
    1998
  • 负责人:
    JANET MCGILL
  • 依托单位:
BRL49653C COMBINATION WITH GLYBURIDE TO PATIENTS WITH DIABETES
  • 批准号:
    6263498
  • 项目类别:
  • 资助金额:
    $2.44万
  • 财政年份:
    1998
  • 负责人:
    JANET MCGILL
  • 依托单位:
海外基金